2019 Biosimilars Immune Response Licensing 
The Pharma Data
FEBRUARY 8, 2021
to €131 million and 12.2%, respectively and benefited from increased demand in metastatic castration-resistant prostate cancer following publication of the results of the CARD study in this disease setting at ESMO (European Society for Medical Oncology) and in the NEJM (New England Journal of Medicine) in September 2019. In the U.S.,
The Pharma Data
FEBRUARY 4, 2021
to €131 million and 12.2%, respectively and benefited from increased demand in metastatic castration-resistant prostate cancer following publication of the results of the CARD study in this disease setting at ESMO (European Society for Medical Oncology) and in the NEJM (New England Journal of Medicine) in September 2019. In the U.S.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 9, 2020
Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2019 May 23;380(21):2082]. Front Immunol. N Engl J Med.
The Pharma Data
DECEMBER 21, 2020
Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2019 May 23; 380 (21): 2082]. Front Immunol.
The Pharma Data
APRIL 27, 2021
net price, increasing usage of Toujeo ® , biosimilar glargine competition and lower sales in Europe (patient stockpilling in the first quarter of 2020). due to the earlier supply to the market as compared to the 2019/2020 flu season. In the U.S., Toujeo ® sales were stable with volume growth offsetting average price decrease.
Expert insights. Personalized for you.
52 
Let's personalize your content